SRR1401953
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR657915 | GTEX | — | 0.947 |
| 2 | SRR1434782 | GTEX | — | 0.940 |
| 3 | SRR613498 | GTEX | — | 0.938 |
| 4 | SRR1476632 | GTEX | — | 0.938 |
| 5 | SRR1475737 | GTEX | — | 0.936 |
| 6 | SRR817258 | GTEX | — | 0.936 |
| 7 | SRR599225 | GTEX | — | 0.936 |
| 8 | SRR655684 | GTEX | — | 0.935 |
| 9 | SRR816292 | GTEX | — | 0.935 |
| 10 | SRR1417981 | GTEX | — | 0.934 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.165 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.158 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.046 | Inavolisib | — uncovered |
| MYOGENESIS | 0.043 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.039 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.036 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.035 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.033 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |